It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but show limited efficacy in EGFR-mutant non-small cell lung cancer (NSCLC).
• Traditional biomarkers like PD-L1 and TILs are unreliable in this specific patient population.
• Combination therapies (e.g., PD-L1 and CTLA-4 inhibitors) present challenges due to toxicity and efficacy concerns.

Purpose of the Study:

• To comprehensively review the current evidence on ICI therapy in EGFR-mutant NSCLC.
• To summarize the potential of ICIs in patients resistant to EGFR-tyrosine kinase inhibitors (TKIs).
• To explore therapeutic strategies for patients progressing on osimertinib or with no T790M mutation.

Main Methods:

• Systematic review of existing literature on ICI therapy in EGFR-mutant NSCLC.
• Analysis of biomarker utility (PD-L1, TILs) in the context of EGFR mutations.
• Evaluation of combination strategies and their efficacy and toxicity profiles.

Main Results:

• Current ICI monotherapy and combination strategies demonstrate inadequate efficacy in EGFR-mutant NSCLC.
• The tumor microenvironment's specificity contributes to the lack of response to ICIs.
• Limited data exists on ICI efficacy in early-stage NSCLC compared to advanced stages.

Conclusions:

• Novel therapeutic strategies are needed to improve ICI efficacy in EGFR-mutant NSCLC.
• Further research is required to identify predictive biomarkers and optimize treatment regimens.
• Exploring ICI potential in TKI-resistant NSCLC warrants further investigation.